| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 33, 1155-1157, Copyright © 1987 by American Association for Clinical Chemistry
N Rifai, RH Christenson, BB Gelman and LM Silverman
Approximately 85% of patients with multiple sclerosis (MS) can be diagnosed by using magnetic resonance imaging and laboratory tests such as determination of the cerebrospinal fluid (CSF) IgG Index and electrophoresis to detect oligoclonal banding. However, these tests results are abnormal in MS patients whether they are in clinical remission or acute exacerbation. Because apolipoprotein E (apo E) is synthesized in the central and peripheral nervous system, particularly during remyelination, we propose that apo E might be a reliable marker of the remyelination that accompanies clinical remission in MS patients. We studied 33 patients with MS, 22 in remission and 11 in exacerbation, and 26 controls of comparable ages. The apo E Index, calculated from the concentrations of apo E and albumin in CSF and serum, allowed us to discriminate between MS patients in remission and MS patients in exacerbation (P less than 0.001); the IgG Index failed to show similar differences. However, combining the apo E and IgG indices gave maximum discrimination between controls, MS patients in remission, and those in exacerbation. This study suggests that apo E measurements should be included in the laboratory evaluation of MS patients.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  L. Julian, L Vella, D Frankel, S. Minden, J. Oksenberg, and D. Mohr ApoE alleles, depression and positive affect in multiple sclerosis Multiple Sclerosis, March 1, 2009; 15(3): 311 - 315. [Abstract] [PDF]
|
|
|
|
|
|
V. Lehmensiek, S. Sussmuth, G. Tauscher, J. Brettschneider, S. Felk, F. Gillardon, and H. Tumani Cerebrospinal fluid proteome profile in multiple sclerosis Multiple Sclerosis, August 1, 2007; 13(7): 840 - 849. [Abstract] [PDF]
|
|
|
|
|
|
D O'Toole and W C Love Interferon-{beta}-1b and interferon-{gamma} have similar inhibitory effects on apolipoprotein-E production in the monocyte/macrophage Multiple Sclerosis, April 1, 2002; 8(2): 124 - 129. [Abstract] [PDF]
|
|
|
|
|
|
P. Hugh, A. Oturai, K. Schreiber, M. Blinkenberg, O. S. Jurgensen, L. Ryder, O. B Paulson, P. S. Surensen, and G. M. Knudsen Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate Multiple Sclerosis, August 1, 2000; 6(4): 226 - 230. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Chapman, C. Sylantiev, P. Nisipeanu, and A. D. Korczyn Preliminary Observations on APOE{epsilon}4 Allele and Progression of Disability in Multiple Sclerosis Arch Neurol, December 1, 1999; 56(12): 1484 - 1487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamauchi, M. Tozuka, T. Nakabayashi, M. Sugano, H. Hidaka, Y. Kondo, and T. Katsuyama Apolipoprotein E in Cerebrospinal Fluid: Relation to Phenotype and Plasma Apolipoprotein E Concentrations Clin. Chem., April 1, 1999; 45(4): 497 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P D Mehta, S D Cook, P K Coyle, R A Troiano, C S Constantinescu, and A M Rostami Free light chains in multiple sclerosis urine Multiple Sclerosis, June 1, 1998; 4(3): 254 - 256. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Schmidt, H. Schmidt, F. Fazekas, M. Schumacher, K. Niederkorn, P. Kapeller, V. Weinrauch, and G. M. Kostner Apolipoprotein E Polymorphism and Silent Microangiopathy-Related Cerebral Damage : Results of the Austrian Stroke Prevention Study Stroke, May 1, 1997; 28(5): 951 - 956. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
